KROS

Keros Therapeutics, Inc. (KROS) 10Y Growth Potential Analysis (2026)

Invetso Score: 4.8/10 — Balanced · Last Updated: 2026-08-01

Overall Score

Revenue Growth Durability

Revenue base remains small, leaving room for growth but also making the path to scale uncertain.

High gross margin suggests the core product can support expansion if demand improves.

Profitability Trajectory

TTM margins remain deeply negative, with operating margin at -6.76% and net margin at -5.54%.

Return metrics are still weak, with ROIC at -35.25% and ROE at -21.40%.

Balance Sheet Strength

Liquidity is very strong, with a current ratio of 21.96 and cash ratio of 21.20.

Leverage remains low, with debt-to-equity at 0.06 and debt-to-assets at 0.05.

Cash Flow Quality

Operating cash flow and free cash flow remain negative on a TTM basis.

Cash conversion is poor despite low capex, indicating the business is still not self-funding.

Capital Efficiency

Asset efficiency remains very low, with asset turnover at 0.05 and fixed asset turnover below 1.0.

Negative returns on invested capital and capital employed indicate weak capital productivity.

Valuation Support

Valuation looks asset-backed, with price-to-book at 0.76 and tangible book value per share above the share price proxy.

However, sales and cash-flow multiples remain elevated or distorted, limiting clear upside support.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Keros Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →